Protagonist Therapeutics, Inc.

PTGX

$145.78

-2.03%

2026-09-04 12:49:34 EDT-$3.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological ...

Price Action of PTGX

$145.78

-2.03%-$3.02

High—

Low—

52W High-9.3%

Rel. vol—

Interval

Range3.3h

Volume—SMA5SMA10

—

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company dedicated to advancing peptide-based drug candidates to address significant unmet medical needs in hematology, inflammation, and immunology. Founded in 2006 and headquartered in Newark, California, the company leverages its proprietary peptide discovery and engineering platform to design both injectable and ...Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company dedicated to advancing peptide-based drug candidates to address significant unmet medical needs in hematology, inflammation, and immunology. Founded in 2006 and headquartered in Newark, California, the company leverages its proprietary peptide discovery and engineering platform to design both injectable and oral therapies with high specificity and stability. The company's pipeline is led by rusfertide (PTG-300), a hepcidin mimetic in Phase II trials for polycythemia vera and hereditary hemochromatosis, and PN-943, an oral alpha-4-beta-7 integrin antagonist for inflammatory bowel disease (IBD). Additionally, PN-235, an oral IL-23 receptor antagonist, is being developed for IBD and other indications. Protagonist has a strategic collaboration with Janssen Biotech, Inc. for the development and commercialization of certain candidates, providing potential milestone payments and royalties. Financially, the company maintains a strong balance sheet with minimal debt, a current ratio of 21.7, and substantial cash reserves, enabling continued investment in R&D (R&D expenses account for ~62% of revenue). Under the leadership of President and CEO Dinesh V. Patel, who brings over 38 years of industry experience, the company has made notable progress, including the recent FDA approval and U.S. launch of Icotyde for psoriasis, a milestone that validates its platform. With a team of approximately 132 employees, Protagonist Therapeutics is positioned to advance its pipeline and deliver innovative therapies to patients.ExpandCollapse

Founded

2006

Employees

141

CEO

Dinesh V. Patel

Full Name

Protagonist Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

12.03%

Market Cap

$9.43B

Current Ratio

21.71

WACC

12.98%

ROIC

10.72%

Contact Information

https://www.protagonist-inc.com

510 474 0170

7707 Gateway Boulevard, Newark, CA 94560

Key Metrics of PTGX

Snapshot

Latest / TTM · 6 periods

Market Cap

$9.43B

ROCE

6.9%

EV / EBITDA

104.95x

+32.2% YoY

FCF Yield

1.4%

+0.4% YoY

Cash Conversion Cycle

-3084.7d

Current Ratio

21.71

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of PTGX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

99.9%

Net Margin

29.4%

P/E Ratio

119.77x

n/a

Debt / Equity

0.01

n/a

Current Ratio

21.71

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of PTGX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $2.43 · Revenue $240.13M · 7 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.26 · Revenue $37.89M · 6 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $4.67 · Revenue $543.43M · 8 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.14 · Revenue $41.42M · 2 analysts

Recent history

Aug 5, 2026
Q2 FY2026 · Results reported
EPS $2.29 · Revenue $213.47M
View filing
May 5, 2026
Q1 FY2026 · Results reported
EPS $0.05 · Revenue $56.37M
View filing
Feb 25, 2026
FY2025 · Annual results
EPS $-2.05 · Revenue $46.02M
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-0.62 · Revenue $4.71M
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $-0.55 · Revenue $5.55M
View filing
May 6, 2025
Q1 FY2025 · Results reported
EPS $-0.19 · Revenue $28.32M
View filing

Financial Statements of PTGX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$46.0M	-89.4%	+278.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-130.1M	-147.3%	+4204.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+97.3%	-2.7%	+0.7%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-343.6%	-690.4%	+1249.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-282.8%	-546.5%	+1036.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$56.1M	-69.3%	+545.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+121.9%	+189.6%	+217.6%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	1.7%	+4.4%	-26.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	12.71x	+1.8%	+22.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$669.9M	-10.0%	+27.0%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-2.05 vs -1.96	-4.3%	2.29 vs 2.23	+2.6%
Revenue Surprise	$46.0M vs $47.0M	-2.2%	$213.5M vs $202.7M	+5.3%

Insider Transactions of PTGX

Acquisitions (A)

Since Jun 10, 2026

Disposals (D)

Since Jun 10, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 11, 2026	PATEL DINESH V PH D	director, officer: President and CEO	Common Stock	A	34,239	$21.58
Aug 11, 2026	PATEL DINESH V PH D	director, officer: President and CEO	Common Stock	D	34,239	$148.52
Aug 11, 2026	PATEL DINESH V PH D	director, officer: President and CEO	Stock Option (right to buy)	D	34,239	$21.58
Aug 10, 2026	PATEL DINESH V PH D	director, officer: President and CEO	Common Stock	A	65,761	$21.58
Aug 10, 2026	PATEL DINESH V PH D	director, officer: President and CEO	Common Stock	D	65,761	$149.11

Leadership Team of PTGX

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Dinesh V. Patel	Chief Executive Officer, President, Secretary & Director	USD 1,414,292	—	1957	Active
Arturo Molina FACP	Chief Medical Officer	USD 949,992	—	1959	Active
Asif Ali	Executive Vice President & Chief Financial Officer	USD 826,242	Male	1974	Active
Carena Spivey	Executive VP & Chief Human Resources Officer	—	Female	—	Active
Ashok Bhandari	EVP & Chief Discovery Officer	—	—	1964	Active
Newman Yeilding	Executive Vice President, Chief Scientific Officer	—	—	—	Active
Carter J. King	Executive Vice President of Business Development	—	Male	1971	Active
Matthew Gosling	Executive Vice President and Chief Legal & Business Officer	—	Male	1971	Active
Venkat Thalladi	EVP & Chief Technical Officer	—	Male	—	Active
Abha Bommireddi	Executive Vice President & Chief of Staff	—	Female	—	Active

Recent News of PTGX

Accesswire6 days agoNeutral

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully Reduce Phlebotomy Burden, and Improve Fatigue Approval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Response During Weeks 20-32 FDA Approval Triggers $275M in Milestones, 14%-29% Royalties, with Up to an Additional $875M in Potential Future Milestones Investor call to be held Monday, August 31st at 8:30 am ET NEWARK, CA / ACCESS Newswire / August 28, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Takeda received U.S. Food and Drug Administration (FDA) approval for MIMRYLO (rusfertide), a subcutaneously delivered first-in-class hepcidin mimetic peptide for the treatment of erythrocytosis in adults with polycythemia vera (PV). MIMRYLO is the first and only hepcidin mimetic approved for polycythemia vera (PV), a blood cancer characterized by excessive production of red blood cells.

Defense World8/28/2026Neutral

Bamco Inc. NY Makes New $1.96 Million Investment in Protagonist Therapeutics, Inc. $PTGX

Bamco Inc. NY bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 16,000 shares of the company's stock, valued at approximately $1,961,000. Several other hedge funds have also made changes to

Accesswire8/18/2026Neutral

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Fool - Investing News8/13/2026Neutral

Which Small-Cap ETF Is the Better Buy: iShares' Growth-Focused IWO or Invesco's Revenue-Weighted RWJ?

Small-cap stocks are surging, but how you own them matters more than most investors realize.

Seeking Alpha8/12/2026Neutral

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for polycythemia vera, with FDA Priority Review decision expected August 2026 and substantial milestone and royalty potential from Takeda. Development pipeline includes oral IL-17 antagonist PN-881 for psoriasis and other inflammatory disorders, with phase 2b study initiation planned for Q1 2027.

Historical Employee Count of PTGX

Current

132

Change

+4.76%

Minimum

105

Maximum

132

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	132	10-K	Feb 25, 2026	View
Dec 31, 2024	126	10-K	Feb 21, 2025	View
Dec 31, 2023	112	10-K	Feb 27, 2024	View
Dec 31, 2022	105	10-K	Mar 15, 2023	View
Dec 31, 2021	118	10-K	Feb 28, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Protagonist Therapeutics, Inc.